This study evaluated the long-term effects of denosumab on trabecular bone score (TBS) and femur strength index (FSI) in postmenopausal women with osteoporosis. Conducted by HealthEast Care System, the observational study involved 86 participants, with 75 completing the study. The findings support denosumab's role in improving bone health metrics over 36 months.